-+ 0.00%
-+ 0.00%
-+ 0.00%

Ovid Therapeutics presents OV329 epilepsy program, targets Phase 2 data in second half of 2027

PUBT·11/10/2026 12:24:10
Listen to the news
Ovid Therapeutics presents OV329 epilepsy program, targets Phase 2 data in second half of 2027
  • Ovid Therapeutics initiated a Phase 2 trial of OV329 in drug-resistant adult focal epilepsy, with data expected in the second half of 2027.
  • An OV329 photoparoxysmal response study is underway, with data expected in the first quarter of 2027.
  • OV329's Phase 1 trial showed no treatment-related serious adverse events or ophthalmic changes.
  • Oral KCC2 activator OV4071 has Phase 1 proof-of-mechanism and ketamine study data expected in the first quarter of 2027.
  • A Phase 2 schizophrenia study of OV4071 is planned for 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.